Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 294Lymphoma 204Lymphoma, Large B-Cell, Diffuse 168Sarcoma 142Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Hodgkin Disease 85Lymphoma, Non-Hodgkin 79Burkitt Lymphoma 67Lymphoma, Follicular 62Leukemia 58Ovarian Neoplasms 51Triple Negative Breast Neoplasms 50Neoplasms 50Lymphoma, Mantle-Cell 48Multiple Myeloma 47Carcinoma, Hepatocellular 47Neuroblastoma 44Neoplasm Metastasis 42Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Recurrence 27Lymphoma, T-Cell, Peripheral 27Osteosarcoma 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Doxorubicin × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡